CMA reveals antitrust investigation into Essential Pharma over bipolar drug
30-11-2020
NHS to receive £8m from Aspen over anti-competitive practices
15-08-2019
CMA accuses 4 pharma companies of anti-competitive conduct
24-05-2019
Sureeporn Teerasatean / Shutterstock.com
African drugmaker Aspen was able to increase its prices for fludrocortisone acetate tablets by 1,800% in the UK, as a result of collusion with two other firms, according to the UK’s Competition and Markets Authority (CMA).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
CMA, competition, antitrust, NHS, Competition and Markets Authority, drug suppliers, Aspen, competition settlement, Amilco, Tiofarma
